E tusa ai ma suʻesuʻega ma Maketi, o le maketi o vailaʻau o le kanesa o le susu o le lalolagi e faʻamoemoe e tupu i le $ 19.49 piliona i le 2025 i le CAGR o le 7.1%. Faatasi ai ma le au atinaʻe biotech o loʻo galulue i le 2022 i togafitiga fou mo le kanesa o le susu o Oncolytics Biotech Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, ma AstraZeneca PLC.
Faatasi ai ma kanesa o loʻo tulimataʻia e le Oncolytics Biotech Inc. ma lana fuʻa immunotherapeutic agent pelareorep, o le kanesa o le susu o le faʻamuamua aloaia lea a le kamupani, e tusa ai ma lana tusi lata mai i tagata e umia sea na toe iloiloina ana mea na ausia i le 2021 ma faʻamatala ai lana polokalame o loʻo lumanaʻi 2022.
I totonu o lana Polokalama Kanesa o le Susu e oʻo mai i le taimi nei, ua molimauina e Oncolytics le sili atu nai lo le faʻaluaina o le ola atoa i metastatic HR + / HER2- maʻi kanesa o le susu na togafitia i le pelareorep i le IND-213-e pei ona vaʻaia mai suʻesuʻega na tuʻuina atu i le 2017.
Ina ua mae'a le su'esu'eina atili o fa'amaumauga, na filifili ai le Oncolytics e taula'i atu i ni fa'amoemoe e tolu e mafai ona fa'atūina e fa'atonu ma pa'aga o vaila'au a le kamupani, e fai ma sui o la'asaga taua mo se su'esu'ega resitala. E aofia ai: 1. Fa'amaonia o le pelareorep e galue e ala i se fa'aogaina o le immunotherapeutic mechanism; 2. Su'esu'eina pe fa'atasi le pelareorep ma fa'agata fa'agata; ma 3. Fa'ailoaina o se biomarker e filifili ai ma'i e foliga mai e sili atu taunu'uga ile falema'i.
E oʻo mai ia Aperila 2021, Oncolytics na tuʻuina atu faʻamaumauga mai lana suʻesuʻega AWARE-1, faʻatautaia ma Roche Holding AG (OTC: RHHBY), faʻaalia ai ua ausia e le kamupani ia sini muamua e lua o loʻo taʻua i luga.
Mulimuli ane ia Tesema i le 2021 San Antonio Breast Cancer Symposium (SABCS), Oncolytics na tuʻuina atu se faʻafouga lelei mo le saogalemu mai lana IRENE Phase 2 Triple-Negative Breast Cancer Trial e iloilo ai le saogalemu ma le aoga o le pelareorep faʻatasi ma le anti-PD-1 inhibitors checkpoint. retifanlimab mai le Incyte Corporation mo togafitiga lona lua po'o le tolu-laina o gasegase e maua i le kanesa o le susu metastatic triple-negative (TNBC).
O faʻamatalaga saogalemu mai le faʻataʻitaʻiga na faʻaalia ai le tuʻufaʻatasiga na faʻafeiloaʻi lelei, e aunoa ma ni popolega saogalemu na maitauina i soʻo se tagata gasegase na lesitala i le faamasinoga i le taimi o le lipoti.
O loʻo faʻaauau pea le suʻesuʻega a le IRENE ma o le a faʻaauau pea ona lesitala tagata mamaʻi i le Rutgers Cancer Institute o New Jersey ma le Ohio State University Comprehensive Cancer Center.
O le Incyte Corporation talu ai nei na tu'uina atu ai se isi fa'afouga e aofia ai lana retifanlimab fa'atasi ma le BriaCell Therapeutics' ta'ita'i ta'ita'i foma'i Bria-IMTTM i le SABCS. Aoteleina i le faʻafouga, o le aofaʻi o le ola na sili atu ona maualuga i tagata mamaʻi i le suʻesuʻega tuʻufaʻatasia, faʻaalia ai se faʻaopoopoga poʻo se mea faʻapitoa ma lagolagoina le faʻaauauina o le suʻesuʻega. E tusa ai ma le upega tafaʻilagi a BriaCell, o faʻamatalaga saogalemu ma aoga e faʻamoemoeina e oʻo atu i le 2022.
O le Pfizer, Inc. na ulufale talu ai nei i se faʻataʻitaʻiga faʻataʻitaʻiga faʻataʻitaʻiga ma le tuʻuina atu o maliega ma Celcuity, lea o le a tuʻuina atu ai e le pharma giant Palbociclib (Ibrance) mo le faʻaaogaina i le vaega 3 suʻesuʻega falemaʻi o loʻo faia e Celcuity e aunoa ma se tau i le kamupani.
O le vaega 3 faʻataʻitaʻiga faʻataʻitaʻiga e faʻamoemoe e amata i le afa muamua o le 2022 e iloilo ai le faʻaogaina o le pan-PI3K / mTOR inhibitor gedatolisib (PF-05212384) faʻatasi ma le palbociclib ma le fulvestrant mo tagata mamaʻi e maua i le estrogen receptor (ER) -positive, HER2 -le kanesa o le susu maualuga. O le a fa'asalalau e Celcuity nisi fa'amatalaga e uiga i su'esu'ega fa'afoma'i pe a mae'a lauga ma fa'amatalaga mulimuli mai le FDA.
I le faaiuga o le 2021, na faasilasila ai e le AstraZeneca PLC ma paaga Daiichi Sankyo o le European Medicines Agency (EMA) na faʻamaonia lana Type II Variation Application mo trastuzumab deruxtecan (T-DXd; Enhertu) mo le togafitiga o le susu HER2 lelei muamua. gasegase o le kanesa.
I le taimi nei, o le tagata maʻi muamua ma HR +, HER2- e le mafai ona faʻaogaina le kanesa o le susu metastatic na faʻaaogaina i le datopotamab deruxtecan (DS-1062a; dato-DXd) o se vaega o le vaega 3 TROPION-Breast01 faʻataʻitaʻiga (NCT05104866). O le TROP2-directed DXd ADC lea o loʻo faʻatulagaina nei e Daiichi Sankyo ma AstraZeneca o loʻo suʻesuʻeina nei i le lalolagi, faʻavasegaina, faʻataʻitaʻiga faʻataʻitaʻiga i se fua o le 6 mg / kg vs filifiliga a le tagata suʻesuʻe o le chemotherapy.
O le isi auala e faaleleia atili ai avanoa i le tau faasaga i le kanesa, o le tuuga e faaleleia vave iloa. E tusa ai ma le Carol Milgard Breast Center o le vave iloa o le ki.
Roche Holding AG talu ai nei na kiki i le $290 miliona i se taamilosaga faʻatupe na sili atu i le $ 1 piliona i le suʻesuʻeina o le biopsy liquid Freenome.
OA MEA E AVEA MAI LENEI TUSI:
- Mulimuli ane ia Tesema i le 2021 San Antonio Breast Cancer Symposium (SABCS), Oncolytics na tuʻuina atu se faʻafouga lelei mo le saogalemu mai lana IRENE Phase 2 Triple-Negative Breast Cancer Trial e iloilo ai le saogalemu ma le aoga o le pelareorep faʻatasi ma le anti-PD-1 inhibitors checkpoint. retifanlimab mai le Incyte Corporation mo togafitiga lona lua po'o le tolu-laina o gasegase e maua i le kanesa o le susu metastatic triple-negative (TNBC).
- Summarized in the update, the overall survival was much higher in the patients in the combination study, suggesting an additive or synergistic effect and supporting the continuation of the study.
- The phase 3 clinical trial is expected to launch in the first half of 2022 assessing the use of the pan-PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with palbociclib and fulvestrant for patients with estrogen receptor (ER)–positive, HER2-negative advanced breast cancer.
